FDA Temporarily Halts Real-Time Disclosure of CRLs for New Drugs, Including AbbVie, Following Citizen Petition
Background of Regulatory Agency's Decision to Halt Information Disclosure
The U.S. Food and Drug Administration (FDA) has temporarily suspended its policy of publicly disclosing Complete Response Letters (CRLs), which detail the reasons for rejecting new drug applications. This decision follows a citizen petition submitted in April by an anonymous pharmaceutical company through the law firm Covington & Burling. Previously, the regulatory agency had been pursuing a 'radical transparency' policy to enhance regulatory transparency and fulfill the right to know for patient groups and researchers. However, concerns grew regarding the unauthorized disclosure of confidential corporate information, leading the agency to halt the policy and re-evaluate improvement measures.
Information Asymmetry and Manufacturing Risks in the Pharmaceutical Industry
Prior to this policy change, the last CRL made available was on April 22, concerning AbbVie's (ABBV) trenibotulinumtoxinE, a botulinum toxin candidate for wrinkle reduction. Subsequently, on June 26, the CRL for Swedish Orphan Biovitrum's (Sobi, SOBIV) NASP, a gout treatment candidate, was not disclosed due to Chemistry, Manufacturing, and Controls (CMC) issues. The concealment of CRLs increases information asymmetry within the industry, raising the risk of repeating similar clinical or manufacturing errors. This can lead to increased costs for developing competing pipelines and delays in new drug development.
Preventing Confidential Information Leaks and Mitigating Corporate Litigation Risks
Pharmaceutical companies have strongly opposed the exposure of their proprietary manufacturing technologies or potential weaknesses in clinical trial designs to competitors. Previously, the surprise public release of Capricor Therapeutics' (CAPR) CRL for deramiocel, a treatment for Duchenne Muscular Dystrophy (DMD), led to corporate legal challenges and rebuttals. Lykos Therapeutics and Stealth BioTherapeutics also reported that confidential information was inadequately redacted during the CRL disclosure process, resulting in information leaks. This suspension is expected to positively impact the prevention of such legal disputes and the protection of corporate intangible asset value.
Formalizing Policy and the Future of Regulatory Guidelines
The regulatory agency is currently working on a Proposed Rule to formalize the authority to disclose CRLs and break with the long-standing practice of considering 'marketing applications themselves confidential.' This enhanced transparency policy, spearheaded by former FDA Commissioner Marty Makary, has gained significant momentum, even leading to calls for legislative amendments at the congressional level. Although currently suspended under the leadership of Acting Commissioner Kyle Diamantas, a more refined Guideline is expected to be finalized upon completion of the regulatory amendments. Investors should pay attention to the balance the agency strikes between protecting commercial secrets and ensuring public transparency.
The FDA's temporary suspension of real-time CRL disclosure is a short-term factor that delays the analysis of manufacturing failure causes for companies facing rejection, increasing information acquisition costs. For example, Swedish Orphan Biovitrum's (Sobi) NASP, which faced a delay in approval due to CMC deficiencies in competition with Amgen's (Amgen) Krystexxa, a drug with annual sales of $1 billion, has indirectly created uncertainty in the design of Phase 3 pipelines in the same industry due to the non-disclosure of specific details in the CRL. In the medium to long term, this may increase the risk of information asymmetry when evaluating global new drug R&D pipelines, potentially putting downward pressure on investment sentiment in the bio sector. Therefore, industry stakeholders and institutional investors should reassess the balance between transparency and technology protection based on the outcome of the non-public citizen petition and the finalized provisions of the Proposed Rule.